Article Text

Download PDFPDF
Haemopoietic stem cell transplantation for genetic disorders
  1. C G Steward,
  2. A Jarisch
  1. Bone Marrow Transplant Unit, Royal Hospital for Children, Bristol, UK
  1. Correspondence to:
    Dr C G Steward
    Bone Marrow Transplant Unit, Royal Hospital for Children, Upper Maudlin Street, Bristol BS2 8BJ, UK; colin.stewardbristol.ac.uk

Abstract

Stem cell transplantation (SCT) is used to cure or greatly ameliorate a wide variety of genetic diseases, ranging from inherent defects of haemopoietic cell production or function to metabolic diseases mostly affecting solid organs. It ranks as one of the most remarkable therapeutic advances of the past 40 years. Despite rapid technological improvements, however, there are still many short term risks and potential long term toxicities. As a consequence, the rapid emergence of alternative therapies (including new drugs, enzyme and gene therapies), necessitate constant re-evaluation of the risk/benefit ratio for each disease and hence the appropriateness of SCT. This review describes the major aspects of the transplant process, indications for transplantation, outcome statistics, and areas where alternative therapies are becoming available.

  • GVHD, graft versus host disease
  • MSD, matched sibling donor
  • MUD, matched unrelated donor
  • PCR, polymerase chain reaction
  • SCID, severe combined immunodeficiency
  • SCT, stem cell transplantation
  • TCD, T-cell depletion
  • haematopoietic stem cell transplantation
  • genetic diseases
  • inborn
  • severe combined immunodeficiency
  • metabolism
  • inborn errors
  • chimerism

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests: none declared